[go: up one dir, main page]

ATE412175T1 - Verwendung von kryptischen peptiden zur induktion von immunologischer toleranz - Google Patents

Verwendung von kryptischen peptiden zur induktion von immunologischer toleranz

Info

Publication number
ATE412175T1
ATE412175T1 AT05011041T AT05011041T ATE412175T1 AT E412175 T1 ATE412175 T1 AT E412175T1 AT 05011041 T AT05011041 T AT 05011041T AT 05011041 T AT05011041 T AT 05011041T AT E412175 T1 ATE412175 T1 AT E412175T1
Authority
AT
Austria
Prior art keywords
immunological tolerance
induce immunological
cryptic peptides
cryptic
peptides
Prior art date
Application number
AT05011041T
Other languages
English (en)
Inventor
Anthony Barrington Kay
Mark Larche
Original Assignee
Circassia Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9605904.3A external-priority patent/GB9605904D0/en
Priority claimed from GBGB9608430.6A external-priority patent/GB9608430D0/en
Application filed by Circassia Ltd filed Critical Circassia Ltd
Application granted granted Critical
Publication of ATE412175T1 publication Critical patent/ATE412175T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43531—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Insects & Arthropods (AREA)
  • Virology (AREA)
AT05011041T 1996-03-21 1997-03-20 Verwendung von kryptischen peptiden zur induktion von immunologischer toleranz ATE412175T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9605904.3A GB9605904D0 (en) 1996-03-21 1996-03-21 Peptides
GBGB9608430.6A GB9608430D0 (en) 1996-04-24 1996-04-24 Peptides

Publications (1)

Publication Number Publication Date
ATE412175T1 true ATE412175T1 (de) 2008-11-15

Family

ID=26308965

Family Applications (2)

Application Number Title Priority Date Filing Date
AT97908389T ATE296444T1 (de) 1996-03-21 1997-03-20 Kryptische peptide und verfahren zu ihrer identifizierung
AT05011041T ATE412175T1 (de) 1996-03-21 1997-03-20 Verwendung von kryptischen peptiden zur induktion von immunologischer toleranz

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT97908389T ATE296444T1 (de) 1996-03-21 1997-03-20 Kryptische peptide und verfahren zu ihrer identifizierung

Country Status (11)

Country Link
US (1) US6737406B1 (de)
EP (2) EP1612555B1 (de)
JP (1) JP4340329B2 (de)
AT (2) ATE296444T1 (de)
AU (1) AU730198C (de)
CA (1) CA2247009C (de)
DE (2) DE69733343D1 (de)
DK (1) DK1612555T3 (de)
ES (1) ES2314515T3 (de)
GB (3) GB2326642B (de)
WO (1) WO1997035193A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2812087B1 (fr) * 2000-07-21 2007-05-11 Inst Nat Sante Rech Med Procede de criblage de peptides utilisables en immunotherapie
JPWO2002066979A1 (ja) * 2001-02-22 2004-06-24 タカラバイオ株式会社 気管支喘息原因抗原の検出方法
AU2003273679A1 (en) * 2002-06-11 2003-12-22 Merck Patent Gmbh Method for mapping and eliminating t-cell epitopes
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
US8652485B2 (en) 2007-08-15 2014-02-18 Circassia Limited Peptide for vaccine

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0271577B1 (de) 1986-06-30 1995-10-04 Massachusetts Institute Of Technology Immunomodulare mittel und deren verwendung
US5019384A (en) 1986-06-30 1991-05-28 Massachusetts Institute Of Technology Immunonodulating compositions and their use
US6180368B1 (en) 1988-03-23 2001-01-30 University Of Melbourne Ryegrass pollen allergen
JP3220451B2 (ja) 1989-03-17 2001-10-22 イミユロジク・フアーマシユーチカル・コーポレーシヨン ブタクサからのアレルゲン蛋白質およびそれらの使用
US5328991A (en) 1989-11-03 1994-07-12 Immulogic Pharmaceutical Corp. Preparation of alkali-modified cat dander allergen (Fel d I) for immunotherapeutic purposes
US5547669A (en) 1989-11-03 1996-08-20 Immulogic Pharma Corp Recombinant peptides comprising T cell epitopes of the cat allergen, Fel d I
EP0500785B1 (de) * 1989-11-03 2002-04-17 Immulogic Pharmaceutical Corporation Aus hausstaub isoliertes t-zellreaktives katzenprotein, und dessen verwendungen
US6019972A (en) * 1989-11-03 2000-02-01 Immulogic Pharmaceutical Corporation Peptides of human T cell reactive feline protein (TRFP)
US5433948A (en) 1990-02-13 1995-07-18 Thomas; Wayne R. Cloning and sequencing of allergens of dermatophagoides (house dust mite)
CA2091449C (en) 1990-09-11 2002-11-05 Wayne R. Thomas Cloning and sequencing of allergens of dermatophagoides (house dust mite)
JPH06506056A (ja) 1990-10-30 1994-07-07 イミュロジック　ファーマシューティカル　コーポレイション Ｍｈｃ抗原によるペプチド結合検定法
WO1992011859A1 (en) 1991-01-08 1992-07-23 Immulogic Pharmaceutical Corporation Peptide-mediated hyposensitization of the human t cell response to dermatophagoides spp. (house dust mite)
WO1994001560A1 (en) 1991-07-12 1994-01-20 Immulogic Pharmaceutical Corporation Allergenic proteins and peptides from japanese cedar pollen
EP0595855A1 (de) 1991-07-12 1994-05-11 Immulogic Pharmaceutical Corporation Allergenische proteine und peptide von japanischen zederpollen
AU682658B2 (en) * 1991-10-16 1997-10-16 Merck Patent Gmbh Recombitope peptides
AU676668B2 (en) 1991-10-16 1997-03-20 Merck Patent Gmbh T cell epitopes of the major allergens from dermatophagoides(house dust mite)
WO1994024281A1 (en) 1993-04-14 1994-10-27 Immulogic Pharmaceutical Corporation T cell epitopes of the major allergens from dermatophagoides (house dust mite)
IL105153A (en) * 1992-03-25 1999-12-22 Immulogic Pharma Corp Therapeutic compositions comprising peptides derived from human t cell reactive feline protein
EP0636180A1 (de) 1992-04-09 1995-02-01 Immulogic Pharmaceutical Corporation T-zellen epitopen vom hauptallergen von ambrosia artemsiifolia
WO1994003478A1 (en) 1992-07-31 1994-02-17 Immulogic Pharmaceutical Corporation Sensitive assay for antigens and antibodies and its use to identify rheumatoid arthritis antigen
WO1994011512A2 (en) 1992-11-12 1994-05-26 Immulogic Pharmaceutical Corporation Allergenic proteins and peptides from japanese cedar pollen
WO1994016068A2 (en) 1992-12-31 1994-07-21 Immulogic Pharmaceutical Corporation Allergenic proteins and peptides from dog dander and uses therefor
FI954269A7 (fi) 1993-03-12 1995-09-12 Immulogic Pharma Corp Raiheinäsiitepölyallergeenin T-soluepitoopit
CA2164326A1 (en) * 1993-06-02 1994-12-08 Wayne Robert Thomas Cryptic peptides for use in inducing immunologic tolerance
WO1995001597A2 (en) 1993-07-01 1995-01-12 British Telecomm System for generating instructions for speech application
NZ271818A (en) 1993-08-13 1997-11-24 Immulogic Pharma Corp T cell epitopes of ryegrass pollen antigen
WO1995026980A2 (en) 1994-04-01 1995-10-12 Immulogic Pharmaceutical Corporation Haptenated peptides and uses thereof
KR100379161B1 (ko) 1994-04-14 2003-06-11 이뮤로직 파마시티컬 코포레이션 집먼지진드기에의한알레르기를치료하기위한의학적펩티드조성물
EP0783322A1 (de) 1994-09-02 1997-07-16 Immunologic Pharmaceutical Corporation Peptidzusammensetzungen mit der fähigkeitantigenspezifische immunantworten herunterregulieren zu können
BR9509438A (pt) 1994-10-25 1997-12-23 Immulogic Pharma Corp Composições e tratamento para a esclerose múltipla
AU4146796A (en) 1994-10-27 1996-05-23 Immulogic Pharmaceutical Corporation T cell epitopes of the major allergens from ambrosia artemisiifolia
AU4695296A (en) 1995-01-06 1996-07-24 Immulogic Pharmaceutical Corporation Compositions and methods for treating rheumatoid arthritis
WO1997032600A1 (fr) 1996-03-10 1997-09-12 Meiji Milk Products Co., Ltd. Agent immunotherapeutique a base peptidique pour le traitement des allergies
US5804201A (en) 1996-03-11 1998-09-08 The Rockefeller University Immunomodulatory peptides of vespid antigen 5

Also Published As

Publication number Publication date
CA2247009C (en) 2009-08-04
EP0888541A1 (de) 1999-01-07
GB2349463B (en) 2001-01-10
EP0888541B1 (de) 2005-05-25
GB2352518A (en) 2001-01-31
AU730198B2 (en) 2001-03-01
GB2349463A (en) 2000-11-01
CA2247009A1 (en) 1997-09-25
ES2314515T3 (es) 2009-03-16
AU730198C (en) 2002-03-14
US6737406B1 (en) 2004-05-18
ATE296444T1 (de) 2005-06-15
DE69739062D1 (de) 2008-12-04
GB2326642B (en) 2001-02-07
GB0027373D0 (en) 2000-12-27
GB0020260D0 (en) 2000-10-04
EP1612555A1 (de) 2006-01-04
GB2326642A (en) 1998-12-30
JP2000508627A (ja) 2000-07-11
WO1997035193A1 (en) 1997-09-25
EP1612555B1 (de) 2008-10-22
DK1612555T3 (da) 2009-02-09
JP4340329B2 (ja) 2009-10-07
AU2036597A (en) 1997-10-10
DE69733343D1 (de) 2005-06-30
GB2352518B (en) 2001-04-04
GB9817461D0 (en) 1998-10-07

Similar Documents

Publication Publication Date Title
HU9501276D0 (en) Stabile, liophylised composition containing proteins
DE69427370D1 (de) Neue integrinbindende peptide
DE4393381T1 (de) Peptide
ATE76309T1 (de) Dialyseloesung und ihre herstellung unter verwendung von peptiden auf der basis von glycin.
FI954559A0 (fi) YY-peptidin analogit ja niiden käytöt
DE69526801D1 (de) Aerosolformulierungen mit peptiden und proteinen
DK6893D0 (da) Peptid
DE69333921D1 (de) "enhancer" sequenz zur modulation der expression in epithelialzellen
DE69326255D1 (de) Elam-1 bindende peptide und zusammensetzungen
ATE412175T1 (de) Verwendung von kryptischen peptiden zur induktion von immunologischer toleranz
FI961634L (fi) Antitromboottisia atsasykloalkyylialkanoyyli peptidejä ja pseudopeptidejä
DE69427363D1 (de) Plättchenaggregationsinhibierende peptide
KR900011858A (ko) 혼성 아미노 수지 조성물
FI943218A7 (fi) Kaseinomakropeptidin peptidit, mainittujen peptidien vasta-aineet ja k äytöt
ZA946887B (en) Novel proteins/polypeptides and cotransfection plasmics and live recombinant carriers therefor
DE69534738D1 (de) Leukocyten-aktivierender Faktor
FI885301A7 (fi) Tekijä VIII:n puhdistuksessa käyttökelpoisia peptidejä
KR900011857A (ko) 혼성 아미노 수지 조성물
DK0779297T3 (da) Antigene peptider med glycinsubstitutioner
NO177858C (no) Peptid
KR900011855A (ko) 혼성 아미노 수지 조성물
DE69420044D1 (de) Blutregulierende peptide
IT9019021A0 (it) Composizioni a base di prolina,glicina e lisina per il trattamento della carenza di collagene
ATE310083T1 (de) Deprenyl induziertes protein
DE69030316D1 (de) Schrittweiser c-terminaler abbau von peptiden und proteinen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1612555

Country of ref document: EP